San-Gang Wu1, Wen-Wen Zhang2, Jun Wang1, Yong Dong3, Jia-Yuan Sun2, Yong-Xiong Chen4, Zhen-Yu He2. 1. Department of Radiation Oncology, Xiamen Cancer Hospital, the First Affiliated Hospital of Xiamen University, Xiamen 361003, PR China. 2. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, PR China. 3. Department of Oncology, the 3rd People's Hospital of Dongguan City, Dongguan 523326, PR China. 4. Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology & Visual Science, Medical College, Xiamen University, Xiamen 361005, PR China.
Abstract
AIM: To assess the outcomes of breast cancer subtype in inflammatory breast cancer (IBC). METHODS: We retrospectively assessed IBC patients from the SEER program. RESULTS: We identified 626 patients, including 230 (36.7%),100 (17.6%), 113 (18.1%), and 173 (27.6%) patients with HoR+/HER2-, HoR+/HER2+, HoR-/HER2+, and HoR-/HER2- subtype disease, respectively. Multivariate analysis demonstrated that, using HoR+/HER2- subtype as reference, patients with HoR+/HER2+ subtype had better breast cancer-specific survival (BCSS) and overall survival (OS), and patients with HoR-/HER2- subtype had worse BCSS and OS, while BCSS and OS were comparable for HoR-/HER2+ subtype. Similar trends were observed in patients who received surgery, radiotherapy, chemotherapy or trimodality therapy. CONCLUSION: Breast cancer subtype is clinically useful for predicting survival outcome in IBC. The HoR+/HER2- subtype shows poorer survival outcome than HoR+/HER2+ subtype.
AIM: To assess the outcomes of breast cancer subtype in inflammatory breast cancer (IBC). METHODS: We retrospectively assessed IBC patients from the SEER program. RESULTS: We identified 626 patients, including 230 (36.7%),100 (17.6%), 113 (18.1%), and 173 (27.6%) patients with HoR+/HER2-, HoR+/HER2+, HoR-/HER2+, and HoR-/HER2- subtype disease, respectively. Multivariate analysis demonstrated that, using HoR+/HER2- subtype as reference, patients with HoR+/HER2+ subtype had better breast cancer-specific survival (BCSS) and overall survival (OS), and patients with HoR-/HER2- subtype had worse BCSS and OS, while BCSS and OS were comparable for HoR-/HER2+ subtype. Similar trends were observed in patients who received surgery, radiotherapy, chemotherapy or trimodality therapy. CONCLUSION:Breast cancer subtype is clinically useful for predicting survival outcome in IBC. The HoR+/HER2- subtype shows poorer survival outcome than HoR+/HER2+ subtype.
Entities:
Keywords:
SEER; inflammatory breast cancer; prognosis; subtype; survival; treatment
Authors: Theresa Relation; Yaming Li; James L Fisher; Allan Tsung; Bridget Oppong; Mariam F Eskander; Samilia Obeng-Gyasi Journal: Surgery Date: 2021-11-30 Impact factor: 3.982
Authors: Tithi Biswas; Charulata Jindal; Timothy L Fitzgerald; Jimmy T Efird Journal: Int J Environ Res Public Health Date: 2019-01-04 Impact factor: 3.390